|Patients: This Phase I study involved 29 patients with a variety of different cancers. One patient had mesothelioma.|
Treatment: The treatment consisted of injections of recombinant human interleukin-12 (a protein).
Toxicity: Toxicities for all patients included grade 4 lymphopenia, and grade 3 or less nausea, vomiting, fatigue, fever, infection, and abdominal pain.
Results: Of 29 patients, two experienced complete response – the patient with mesothelioma is without progression at two years.
Correspondence: Ralph S. Freedman, MD